Response to Treatment Series: Part 2, tumor response assessment - Using new and conventional criteria

American Journal of Roentgenology

Volumn 197, Issue 1, 2011, Pages 18-27

  Yaghmai, Vahid ^a   Miller, Frank H ^a   Rezai, Pedram ^a   Benson III, Al B ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Choi criteria; EASL; Imaging biomarkers; Oncologic imaging; RECICL; RECIST; Tumor response

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CYTOTOXIC AGENT; FLUORODEOXYGLUCOSE F 18; IMATINIB; IODINATED POPPYSEED OIL; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; YTTRIUM 90;

ABDOMINAL TUMOR; ANTINEOPLASTIC ACTIVITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CRITERION VARIABLE; CYTOSTASIS; DISEASE COURSE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GROWTH INHIBITION; HEALTH CARE ORGANIZATION; HUMAN; IMAGING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPH NODE; MICROSCOPIC ANATOMY; MOLECULAR IMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONE DIMENSIONAL IMAGING; OUTCOME ASSESSMENT; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REPRODUCIBILITY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SOFT TISSUE SARCOMA; SOLID TUMOR; STANDARDIZATION; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; TWO DIMENSIONAL IMAGING; VOLUMETRY; WORLD HEALTH ORGANIZATION;

HUMANS; MOLECULAR IMAGING; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 79960476903     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.6581     Document Type: Note

References (76)

1. Cademartiri F, Luccichenti G, Maffei E, et al. Imaging for oncologic staging and follow-up: review of current methods and novel approaches. Acta Biomed 2008; 79:85-91
2. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009; 15:406-420
3. Sawyers CL. The cancer biomarker problem. Nature 2008; 452:548-552 (Pubitemid 351483368)
4. Van Beers BE, Vilgrain V. Biomarkers in abdominal imaging. Abdom Imaging 2009; 34:663-667
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95
6. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24:3245-3251 (Pubitemid 46622065)
7. Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging 2006; 6:S126-S130
8. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are Response Evaluation Criteria in Solid Tumors reliable? Cancer 2009; 115:616-623
9. Gwyther SJ, Schwartz LH. How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer 2008; 44:39-45 (Pubitemid 350256945)
10. Saini S. Radiologic measurement of tumor size in clinical trials: past, present, and future. AJR 2001; 176:333-334 (Pubitemid 32105637)
11. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 2002; 225:416-419 (Pubitemid 35239241)
12. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis - Meta-Analysis Group in Cancer. Lancet 2000; 356:373-378 (Pubitemid 30487493)
13. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 2008; 26:1346-1354
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214 (Pubitemid 11167383)
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
16. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008; 28:329-344
17. Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 1984; 2:1040-1046 (Pubitemid 14026263)
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
19. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009; 72:217-238
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(suppl 1):122S-150S
21. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42:1031-1039
22. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR 2010; 195:281-289
23. Hilsenbeck SG, Von Hoff DD. Measure once or twice: does it really matter? J Natl Cancer Inst 1999; 91:494-495 (Pubitemid 29157057)
24. Rezai P, Mulcahy MF, Tochetto SM, Berggruen S, Yaghmai V. Morphological analysis of pancreatic adenocarcinoma on multidetector row computed tomography: implications for treatment response evaluation. Pancreas 2009; 38:799-803
25. Bornemann L, Kuhnigk JM, Dicken V, et al. Informatics in radiology (infoRAD): new tools for computer assistance in thoracic CT. Part 2. Therapy monitoring of pulmonary metastases. Radio-Graphics 2005; 25:841-848 (Pubitemid 40826802)
26. Keil S, Plumhans C, Behrendt FF, et al. Semi-automated quantification of hepatic lesions in a phantom. Invest Radiol 2009; 44:82-88
27. Tran LN, Brown MS, Goldin JG, et al. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol 2004; 11:1355-1360 (Pubitemid 39642822)
28. Baghi M, Mack MG, Hambek M, et al. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. Head Neck 2007; 29:104-108 (Pubitemid 46167776)
29. Beer AJ, Wieder HA, Lordick F, et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 2006; 239:472-480
30. Lee SM, Kim SH, Lee JM, et al. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdom Imaging 2009; 34:430-440
31. Baghi M, Bisdas S, Engels K, et al. Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer. Clin Otolaryngol 2007; 32:372-377 (Pubitemid 47460295)
32. van den Broek GB, Rasch CR, Pameijer FA, et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 2004; 101:1809-1817 (Pubitemid 39314744)
33. Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours: a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004; 90:2256-2260 (Pubitemid 38961886)
34. Heussel CP, Meier S, Wittelsberger S, Gotte H, Mildenberger P, Kauczor HU. Follow-up CT measurement of liver malignoma according to RECIST and WHO vs. volumetry [in German]. Rofo 2007; 179:958-964 (Pubitemid 47596421)
35. Fabel M, von Tengg-Kobligk H, Giesel FL, et al. Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV: a feasibility study. Eur Radiol 2008; 18:1114-1122
36. Rohde S, Turowski B, Berkefeld J, Kovács AF. CT-based evaluation of tumor volume after intraarterial chemotherapy of locally advanced carcinoma of the oral cavity: comparison with clinical remission rates. Cardiovasc Intervent Radiol 2007; 30:85-91 (Pubitemid 44900495)
37. Wormanns D, Kohl G, Klotz E, et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility. Eur Radiol 2004; 14:86-92 (Pubitemid 38181058)
38. Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from sameday repeat CT scans of patients with non-small cell lung cancer. Radiology 2009; 252:263-272
39. Jennings SG, Winer-Muram HT, Tarver RD, Farber MO. Lung tumor growth: assessment with CT - comparison of diameter and cross-sectional area with volume measurements. Radiology 2004; 231:866-871 (Pubitemid 38668110)
40. Belton AL, Saini S, Liebermann K, Boland GW, Halpern EF. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol 2003; 58:311-314 (Pubitemid 36416974)
41. Obuchowski NA. How many observers are needed in clinical studies of medical imaging? AJR 2004; 182:867-869 (Pubitemid 38391644)
42. 18F-FDG PET. J Nucl Med 2009; 50(suppl 1):97S-105S
43. Pasetto LM, Bortolami A, Falci C, Sinigaglia G, Monfardini S. Recent progress in target therapy in colorectal cancer. Anticancer Res 2006; 26:3973-3981 (Pubitemid 44701485)
44. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684 (Pubitemid 41464706)
45. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303:1062-1069
46. Boss A, Clasen S, Kuczyk M, Schick F, Pereira P. Image-guided radiofrequency ablation of renal cell carcinoma. Eur Radiol 2007; 17:725-733
47. Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. RadioGraphics 2008; 28:379-390; discussion, 390-392
48. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235:892-898 (Pubitemid 40695886)
49. Miller FH, Keppke AL, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR 2007; 188:776-783
50. Rhee TK, Naik NK, Deng J, et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008; 19:1180-1186
51. Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011; 54:695-704
52. 90Y help predict metabolic activity at FDG PET? Radiology 2010; 255:164-172
53. Spira D, Fenchel M, Lauer UM, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011; 18:89-96
54. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR 2004; 183:1619-1628 (Pubitemid 44210530)
55. Gopinath G, Ahmed A, Buscombe JR, Dickson JC, Caplin ME, Hilson AJ. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging. Nucl Med Commun 2004; 25:253-257 (Pubitemid 38393516)
56. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010; 194:157-165
57. Sleijfer S, Wiemer E, Verweij J. Drug insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 2008; 5:102-111 (Pubitemid 351188931)
58. Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 2006; 79:e40-e44
59. Van den Abbeele AD. The lessons of GIST: PET and PET/CT - a new paradigm for imaging. Oncologist 2008; 13(suppl 2):8-13
60. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760-1764 (Pubitemid 46797958)
61. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102:803-809
62. Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009; 251:447-456
63. Bruix J, Sherman M, Llovet JM, et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference - European Association for the Study of the Liver. J Hepatol 2001; 35:421-430 (Pubitemid 32844200)
64. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40:1352-1360 (Pubitemid 39657009)
65. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009; 250:466-473
66. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49:1185-1193
67. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60
68. Kudo M, Kubo S, Takayasu K, et al.; for The Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). Hepatol Res 2010; 40:686-692
69. Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. RadioGraphics 2008; 28:81-99
70. Kim YS, Rhim H, Lim HK. Imaging after radio-frequency ablation of hepatic tumors. Semin Ultrasound CT MR 2009; 30:49-66
71. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR 2009; 193:1044-1052
72. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR 2003; 181:708-710 (Pubitemid 37021839)
73. Meijerink MR, van Waesberghe JH, van der Weide L, et al. Early detection of local RFA site recurrence using total liver volume perfusion CT: initial experience. Acad Radiol 2009; 16:1215-1222
74. Yaghmai V, Tochetto SM, Galizia MS, et al. Enhancing tumor volume quantification on MDCT as the predictor of hepatocellular carcinoma response to 90-yttrium (90Y) radioembolization therapy (abstr). Orlando, FL: The Society of Gastrointestinal Radiologists. 2010
75. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586 (Pubitemid 350002966)
76. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yt-trium-90 microspheres. AJR 2007; 188:768-775